Vertex reports $75 million in telaprevir revenues in Q2
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals reported net revenues of around $75 million for Incivek (telaprevir) in the second quarter. The new hepatitis C drug was approved in the US on 23 May (scripintelligence.com, 23 May 2011) and received a positive opinion from the CHMP in Europe on 22 July.